Dan Hurley, award-winning journalist and author of the new book Diabetes Rising is turning out to have some controversial views. He certainly thinks about Type 1 diabetes — which he’s lived with himself for 34 years — in different terms than I do; he’s very focused on causes and prevention, while I’m just trying to work out how to live with this thing. When I approached Dan to write a piece here at the ‘Mine…Read more »
Today, another example of the more things change, the more they stay the same:
In his new book Diabetes Rising, journalist Dan Hurley reports about skyrocketing numbers of children being diagnosed with Type 1 diabetes in a wealthy Boston suburb. Parents there are desperate for answers as to why this is happening, yet “the lack of a national or even statewide diabetes registry complicates efforts… we know little about what causes Type 1 diabetes.”
When the JDRF recently announced its newest artificial pancreas push — a partnership with Animas and Dexcom to actually develop a commercial product — head of the project Aaron Kowalski kindly agreed to answer reader questions here.
Today, I bring you those answers, direct “from the horses’ mouth,” as it were.
Q) How much more advanced will this be than the Medtronic Paradigm Veo system launched in Europe, which stops insulin delivery for…
Very big news in the diabetes world today, Folks: the Juvenile Diabetes Research Foundation (JDRF) has announced a partnership with insulin pump makers Animas Corp. (a Johnson & Johnson company) to actually start building the first ready-for-market artificial pancreas, i.e. “a fully automated system to dispense insulin … based on real-time changes in blood sugar levels.” DexCom will provide the continuous glucose monitoring (CGM) technology for the new system being developed.
I was fortunate to…
At the end of last year (so, basically, two weeks ago), the Juvenile Diabetes Research Foundation announced a joint partnership with the Johnson & Johnson Corporate Office of Science and Technology to help with the discovery and development of drugs to promote beta cell survival. The program will look to fund research at academic centers around the world that could eventually lead to novel new drugs for the prevention and treatment of type 1 diabetes.…Read more »